Clinical evaluation of tumor targeting with the anticarcinoembryonic antigen murine monoclonal antibody fragment, MN-14 F(ab)2

Cancer

Volumn 78, Issue 1, 1996, Pages 157-168

  Juweid, Malik ^a   Sharkey, Robert M ^a   Behr, Thomas M ^a   Swayne, Lawrence C ^a   Dunn, Robert ^a   Ying, Zhiliang ^b   Siegel, Jeffry A ^a   Hansen, Hans J ^c   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c IMMUNOMEDICS INC   (United States)

Author keywords

carcinoembryonic antigen; clinical studies; dosimetry; external scintigraphy; pharmacokinetics; radiolabeled monoclonal antibody; targeting

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY MN 14; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG HALF LIFE; FEMALE; HUMAN; ISOTOPE LABELING; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; SOLID TUMOR; TARGET CELL DESTRUCTION; TUMOR SCINTISCANNING;

ADOLESCENT; ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; CARCINOEMBRYONIC ANTIGEN; FEMALE; HALF-LIFE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOTOXINS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0029892932     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960701)78:1<157::AID-CNCR22>3.0.CO;2-Y     Document Type: Article

References (48)

1. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965;121:439-62.
2. Goldenberg DM, DeLand F, Kim E, Bennett S, Primus FJ, van Nagell JR, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978;298:1384-8.
3. Goldenberg DM, Kim EE, DeLand FH, Bennett S, Primus FJ. Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen. Cancer Res 1980;40:2984-92.
4. Sharkey RM, Goldenberg DM, Goldenberg H, Lee RE, Ballance C, Pawlyk D, et al. Murine monoclonal antibodies against carcinoembryonic antigen: immunological, pharmacokinetic, and targeting properties in humans. Cancer Res 1990;50:2823-31.
5. 99mTc. Cancer Res 1990;50:909-21.
6. Swayne LC, Goldenberg DM, Diehl WL, Macaulay RD, Derby LA, Trivino JZ. SPECT anti-CEA monoclonal antibody detection of occult colorectal carcinoma metastases. Clin Nucl Med 1991;16:849-52.
7. 99mTc-labeled anti-CEA monoclonal antibody Fab′ fragments: experience in a large community hospital. Antib Immunoconjug Radiopharm 1991;4:553-60.
8. Serafini AN, Vargas-Cuba R, Benedetto P, Ardalan B, Garrido J, Robinson D, et al. Technetium-99m-labeled Fab′ fragment of anti-CEA monoclonal antibody for radioimmunodetection of colorectal adenocarcinoma. Antib Immunoconjug Radiopharm 1991;4:561-8.
9. 99mTc [abstract]. J Nucl Med 1991;32:1101.
10. 99mTc-labeled antibody fragment (IMMU-4 Fab′) in colorectal cancer patients [abstract]. J Nucl Med 1991;32:1051.
11. Behr TM, Becker WS, Bair HJ, Klein MW, Stuhler CM, Cidlinsky KP, et al. Comparison of complete versus fragmented technetium-99m-labeled anti-CEA monoclonal antibodies for immunoscintigraphy of colorectal cancer. J Nucl Med 1995;36:430-41.
12. 131I-labeled anti-CEA antibodies. J Nucl Med. 1996;37:875-81.
13. Hansen HJ, Goldenberg DM, Newman E, Grebenau R, Sharkey RM. Characterization of second generation monoclonal antibodies against carcinoembryonic antigen. Cancer 1993; 71:3478-85.
14. Sharkey RM, Goldenberg DM, Murthy S, Pinsky H, Vagg R, Pawlyk D, et al. Clinical evaluation of tumor targeting with a high-affinity anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. Cancer 1993;71:2081-96.
15. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988;48:2641-58.
16. Blumenthal RD, Sharkey R, Goldenberg D. Cancer perspectives and changes in the use of monoclonal antibodies in the imaging and therapy. Adv Drug Rev 1990;4:279-318.
17. 2. J Nucl Med 1983;24:316-325.
18. 131I-labelled antibodies and their fragments in the GW-39 colonic cancer xenograft model. Int J Cancer 1989; 44:292-300.
19. 2 in nude mice bearing human tumor xenografts. Cancer 1994;73:817-23.
20. 2 fragments. J Clin Invest 1989;83:1449-56.
21. 2 fragment in experimental ovarian cancer. Br J Cancer 1992;65:677-83.
22. 2, and Fab in tumors. Cancer Res 1989;49:5656-63.
23. Thomas GD, Chappell MJ, Dykes PW, Ramsden DB, Goodfrey KR, Ellis JRM, et al. Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: a biomathematical model. Cancer Res 1989;49:3290-6.
24. Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, Van Osdol W, et al. The micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence of a binding site barrier. Cancer Res 1992;52:5144-53.
25. Primus FJ, Newell KD, Blue A, Goldenberg DM. Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies. Cancer Res 1983;43:686-92.
26. Weadock KS, Sharkey RM, Varga DC, Goldenberg DM. Evaluation of a remote radioiodination system for radioimmunotherapy. J Nucl Med 1989;31:508-11.
27. Hoffman T. Points to consider in the manufacture and testing of monoclonal antibody products for human use [memorandum, Rockville, MD]. Office of Biologics Research and Review, Center for Drugs and Biologics, Food and Drug Administration, 1987.
28. Primus FJ, Kelley EA, Hansen HJ, Goldenberg DM. "Sandwich"-type immunoassay for carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and management of cancer. Clin Chem 1988;34:261-4.
29. 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 1990;50:1039-42.
30. Siegel JA, Goldenberg DM, Sharkey RM, Hall TC, Murthy S, Lee RE, et al. Tumor and organ dosimetry for I-131-labeled LL2 (EPB-2) monoclonal antibody in patients with B-cell lymphomas. Antib Immunoconj Radiopharm 1991;4:649-54.
31. Synder WS, Ford MR, Warner GG, Watson SB. "S" absorbed dose per unit cumulative activity for selected radionuclides and organs. New York: Society of Nuclear Medicine; 1975. Medical Internal Radiation Dose Pamphlet No.: 11.
32. Halpern SE, Haindl W, Beauregard J, Hagan P, Clutter M, Amox D, et al. Scintigraphy with In-111-labeled monoclonal antitumor antibodies: kinetics, biodistribution, and tumor detection. Radiology 1988;168:529-36.
33. Patt YZ, Lamki LM, Haynie TP, Unger MW, Rosenblum MG, Shirkhoda A, et al. Improved tumor localization with increasing dose of In-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 in metastatic colorectal cancer. J Clin Oncol 1988;6:1220-30.
34. 2 in patients with advanced colorectal carcinoma. Antib Immunoconj Radiopharm 1993;6:239-55.
35. Thomas P, Toth CA, Saini KS, Jessup JM, Steele G Jr. The structure, metabolism, and function of the carcinoembryonic antigen gene family. Biochim Biophys Acta 1990;1032: 177-89.
36. Behr TM, Sharkey RM, Juweid M, Dunn RM, Wong GY, Siegel JA, et al. Influence of antibody protein dose on the dosimetry and diagnostic accuracy in radioimmunodetection (RAID) and therapy (RAIT) of CEA-expressing tumors (abstract). J Nucl Med 1995;36:226.
37. 2 fragments of anti-CEA monoclonal antibody, Cancer Detect Prevent 1987;10:335-45.
38. 2 fragments of an anti-carcinoembryonic antigen monoclonal antibody: a multicenter study. Cancer Res 1989;49:3095-103.
39. 2 fragments of an anti-CEA MoAb (abstract). Br J Cancer 1985;52:649.
40. 2 fragments of anti-CEA monoclonal antibody F023C5. Nucl Med Commun 1988;9:577-89.
41. Gasparini M, Ripamonti M, Seregini E, Regalia E, Buraggi GL. Tumor imaging of colorectal carcinoma with anti-CEA monoclonal antibody. Int J Cancer 1988;81-4.
42. 2 BW 431/31) against CEA: radiolabelling, antibody kinetics and distribution findings in tumour and nontumour patients. Nucl Med Commun 1989;10:627-41.
43. 2 fragment of anti-CEA monoclonal antibody Radiology 1990;174:147-51.
44. 111In-labeled anti-CEA monoclonal antibody. Am J Radiol 1988;151:697-703.
45. 2 in colorectal cancer patients. Cancer 1994;73:850-7.
46. 2 fragments in ovarian carcinoma patients. Concer Res 1993;53:5413-18.
47. Sharkey RM, Goldenberg DM, Vagg R, Pawlyk D, Wong G, Siegel JA, et al. Phase I clinical evaluation of a new murine monoclonal antibody (Mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas. Cancer 1994; 73:863-77.
48. Courtenay-Luck NS, Epenetos AA, Moore R, Larche M, Pectasides D, Dhokia B, et al. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res 1986;46:6489-93.